ABBV/ENTA will start a phase-1 trial of ABT-493 (ENTA’s next-gen PI, which is licensed to ABBV) + ABT-530 (ABBV’s own next-generation NS5A) in 3Q13. Unlike ABT-450, ABT-493 does not require ritonavir boosting and it is small enough to be combined with ABT-530 in a single qD tablet.
The combination may have utility beyond genotype-1, although the companies have not yet made specific claims. (Source: ENTA’s recent WF webcast.)
Market Data 
Markets 
AI
